Press Releases April 12, 2026 08:00 PM

Celldex to Present at Upcoming Investor Conference

Celldex to participate in fireside chat at H.C. Wainwright's 4th Annual Inflammatory Skin Disease Virtual Conference

By Hana Yamamoto CLDX
Celldex to Present at Upcoming Investor Conference
CLDX

Celldex Therapeutics announced that its management will present and participate in a fireside chat at the upcoming H.C. Wainwright Inflammatory Skin Disease Virtual Conference. The event will be webcast and replays will be available for 90 days, highlighting Celldex's commitment to advancing novel antibody-based immunology therapies targeting allergic, inflammatory, and autoimmune disorders.

Key Points

  • Celldex management will engage with investors and industry participants during the April 14 virtual conference.
  • The company focuses on developing antibody-based therapies targeting immune system pathways for inflammatory and autoimmune diseases.
  • The webcast presentation aims to enhance investor awareness and showcase Celldex's progress in immunology drug development.

HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at H.C. Wainwright’s 4th Annual Inflammatory Skin Disease Virtual Conference on Tuesday, April 14 at 3:30 pm ET.

The webcast of the presentations will be available on the "Events & Presentations" page of the "Investors" section of the Celldex website. Replays will be available for 90 days following the event.

About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.
Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
[email protected]

Patrick Till
Meru Advisors
(484) 788-8560
[email protected]


Risks

  • Clinical and regulatory risks inherent in developing novel immunology therapies could affect future progress.
  • Market reception and competitive landscape in inflammatory and autoimmune disease treatments may impact Celldex's growth.
  • Dependence on successful translation of research into effective therapies presents uncertainty in timelines and outcomes.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026